Aduro Biotech, Inc. CONFIDENTIAL Protocol ADU -CL-02 Final Version 1 Page 1 of 24 04MAY2018 ABBREVIATED FINAL ANALYSIS STATISTICAL ANALYSIS PLAN Aduro Biotech, Inc. Protocol Number: ADU- CL-02 A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS- 207 in Combination with Pemetrexed and Cisplatin as Front -line Therapy in Adults with Malignant Pleural Mesothelioma Protocol Number: ADU- CL-02 Protocol Version: Version 7, 15 November 2016 Name of Test Drug(s): CRS -207 Phase: 1B Sponsor: Aduro Biotech, Inc. 740 Heinz Avenue Berkeley, CA 94710 SAP Author: SAP D ate: 04MAY2018 SAP Version: Abbreviated Version Notice of Confidential and Proprietary Information: The information contained in this document is confidential belonging to Aduro Biotech, Inc.